Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs.

about

Biodistribution and tolerance of intravenous iodine-131-labelled hypericin in healthy dogs.

Item

http://www.wikidata.org/entity/Q48286237

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Biodistribution and tolerance ...... led hypericin in healthy dogs.

@en

Biodistribution and tolerance ...... led hypericin in healthy dogs.

@nl

type

Item

label

Biodistribution and tolerance ...... led hypericin in healthy dogs.

@en

Biodistribution and tolerance ...... led hypericin in healthy dogs.

@nl

prefLabel

Biodistribution and tolerance ...... led hypericin in healthy dogs.

@en

Biodistribution and tolerance ...... led hypericin in healthy dogs.

@nl

P1476

Biodistribution and tolerance ...... lled hypericin in healthy dogs

@en

P2093

A M Kitshoff

http://www.w3.org/2001/XMLSchema#string

F De Vos

http://www.w3.org/2001/XMLSchema#string

H de Rooster

http://www.w3.org/2001/XMLSchema#string

K Peremans

http://www.w3.org/2001/XMLSchema#string

R Dockx

http://www.w3.org/2001/XMLSchema#string

S Daminet

http://www.w3.org/2001/XMLSchema#string

T Bosmans

http://www.w3.org/2001/XMLSchema#string

Y Ni

http://www.w3.org/2001/XMLSchema#string

P2860

New strategies in anti-vascular cancer therapy.

Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.

Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258.

Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection.

TLR9 agonist protects mice from radiation-induced gastrointestinal syndrome.

Hypericin in cancer treatment: more light on the way.

Targeting tumour vasculature: the development of combretastatin A4.

Vascular targeting agents as cancer therapeutics.

Vascular-targeting therapies for treatment of malignant disease.

Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".

P304

318-323

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/VCO.12381

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

E Abma

P577

2018-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29314561

http://www.w3.org/2001/XMLSchema#string